ARTE

TO1

Strengthening research, technological development and innovation

The project in numbers
Duration:
30 months
Start date: 01.10.17
End date: 31.03.20
N. Partner: 6
 
Progress
Budget:
1.285.297,50€
Budget FERS:
1.092.502,87€

The project in numbers

Duration: 
30 months
Start / End: 
01.10.17 to 31.03.20
Project progress: 
100%
Budget: 
1285297.50€
Budget FERS: 
1092502.87€

ARTE

Ecosystem for Advanced Regenerative Medicine Therapies
Priority Axis 1

Promoting innovation capacities for a more competitive area

Specific Objective: 
OS 1.1.
Investment Priority: 
PI 1b
Typology: 
Standard
Overall Objective of the Project: 

The overall goal of the Arte project is to improve cross-border cooperation among hospitals, Research Centres, Universities, SMEs, and Technology Parks, in order to promote the transfer of innovative biomedical techniques for greater competitiveness in the field of regenerative medicine throughout the cross-border area.

Project summary: 

The ARTE project’s challenge has been to transform the program area into a reference point for the European ecosystem for innovative therapies and regenerative medicine (which, with a global market of € 20 billion and a CAGR growth of 36%, is a priority of the EU Commission), by rendering this innovative territory attractive for investments in smart health, as one of the key S3 sectors.

ARTE INTERREG Italy-Slovenia V-A has been a precursor project aligned to the new Pharmaceutical Strategy for Europe. It has primed a durable change in the area's competitiveness, creating a notable HUB in the fast-growing European and global ecosystem of advanced cell therapies, benefiting patients, research, companies, employees, and the economy in general.

 

Ecosystem-building methodology

The Business Ecosystem model has been pursued to involve and support technology companies that have global market potential, putting in place new forms of “collaborative business models” for continuous innovation. This implies above all a business-oriented, open-minded, and dynamic approach, and the capability to activate SME networks in Slovenia, Friuli Venezia Giulia and Italy, as well as globally. Other implemented methodologies include: Open Innovation, Product Platforming, and Tech Risk Array.

By improving cross border cooperation among Hospital structures, R&D Centers, Universities, SMEs, and Technology Parks, ARTE has had the following development objectives:

  • achieve high competitiveness in the field of regenerative medicine,
  • attract Investment and financial resources,
  • prime SME Growth,
  • generate new employment.

FOCUS: ARTE's focus has been Osteoarthritis, a disabling disease affecting over 10% of the adult population and 50% of people over 60. By building upon the achievements of the previous EU Horizon projects, the Partners worked together to make regenerative medicine for musculoskeletal diseases become affordable.

Breakthrough innovations in cell manufacturing developed around the NANT XL system.

Improving Cell Product Manufacturing is central to improve the affordability of new therapies, letting more patients benefit from new solutions. VivaBioCell’s automated bioreactors (“GMP-in-a-Box”) contribute to improving the cost and scalability of manufacturing.

ARTE contributed to developing the next generation family of bioreactors that will embed innovations from several SME suppliers. New solutions include the development of a new software suite to scale production and new optical sensors.

Notably, ARTE has helped EDUCELL d.o.o., a manufacturer of cell therapy products, to gain expertise with “GMP in a Box” tools. This new competence has enabled the Slovenian SME to conclude new very promising international agreements and obtain funding for new investments.

THE VISION OF WORKING AHEAD, TOGETHER

Strong cooperation is essential to bring ground-breaking therapies to patients and create entrepreneurial and employment growth. Implementing the concerted approach outlined in Figure 1 may become the core experiment of a new “Slovenia-Italia Collaborative Advanced Therapies Hub," which would have significant European value as a test-bed for new initiatives in the high-tech sector of Regenerative Medicine. The Hub would encompass various Stakeholders and address both Lead Demand (e.g., public Hospitals and administrations), Innovative Offer (products, services, intellectual property, clinical research), and have an EU/international reach.

Main results: 

The result of the project is increased cooperation among the hospitals, Research Centres, Universities, SMEs, and Technology Parks operating in the biomedical sector through the creation of a cross-border public/private Network aimed at developing and promoting a new innovative treatment in the biomedical field, with the joint development of innovative products and services in regenerative medicine.

Results by the numbers:

  • 5 Clinical research centers collaborating on new therapies
  • 12 public and private organizations involved in innovation
  • 10 SMEs involved in implementing project activities
  • 80 employees of companies and SMEs involved
  • 50 researchers (ATMP production and clinical studies)
  • 12 start-ups; involvement of risk capital
  • 3 biomedical innovations transferred to SMEs
  • 40 SME belonging to networks
  • 19 NEW EMPLOYEES
  • OVER 2.5 million € PRIVATE INVESTMENTS ATTRACTED FROM PRIVATE INVESTORS

Long Lasting results:

  • The Interregional Regenerative Medicine Hub is now operational
  • A Therapeutic Applications pipeline established, including TNBC – Triple Negative Breast Cancer (Interreg Italia-Slovenia ImmunoCluster Project; LP Celica Biomed d.o.o.);
  • FAC – Fight Against Coronavirus consortium formed, submitting a Research Proposal to the IMI EU Programme; IND Investigational New Drug study approved by FDA (US)

Partner

Lead Partner

Tehnološki park Ljubljana d.o.o.

Osrednjeslovenska
SLO

Project partner 1

Ortopedska bolnišnica Valdoltra

Obalno-kraška
SLO

Project partner 2

Univerza v Ljubljani (Fakulteta za farmacijo)

Osrednjeslovenska
SLO

Project partner 3

VIVABIOCELL SPA

Udine
ITA

Project partner 4

Azienda sanitaria universitaria Friuli Centrale

Udine
ITA

Project partner 5

Biovalley Investments S.p.A.

Trieste
ITA

Documents

Poster evento annuale 30/05/2018Poster evento annuale 30/05/2018
ARTE_ITA_1.pdf
( 459 bytes, published on 7 June, 2018 - 12:49 )
PubblicazionePubblicazione
ARTE_FINAL REPORT ENG.pdf
( 4 bytes, published on 23 February, 2022 - 12:58 )
Znanstvena publikacija - Pubblicazione - Scientific PublicationZnanstvena publikacija - Pubblicazione - Scientific Publication
Scietific Pub Čamernika Stem Cell intern .pdf
( 3 bytes, published on 25 February, 2022 - 20:23 )
Znanstvena publikacija - Pubblicazione - Scientific PublicationZnanstvena publikacija - Pubblicazione - Scientific Publication
Scientific Pub Detela EU Reg Pathways for ATMPs.pdf
( 2 bytes, published on 25 February, 2022 - 20:23 )
Znanstvena publikacija - Pubblicazione - Scientific PublicationZnanstvena publikacija - Pubblicazione - Scientific Publication
Scientific Pub Cifu Stem cell international 2020.pdf
( 2 bytes, published on 25 February, 2022 - 20:23 )
Znanstvena publikacija - Pubblicazione - Scientific PublicationZnanstvena publikacija - Pubblicazione - Scientific Publication
Scientific Pub Čamernik2020_Article_IncreasedExhaustionOfTheSubcho (1).pdf
( 2 bytes, published on 25 February, 2022 - 20:23 )
Znanstvena publikacija - Pubblicazione - Scientific PublicationZnanstvena publikacija - Pubblicazione - Scientific Publication
Scientific Pub Čamernik Stem Cell Research & Therapy.pdf
( 3 bytes, published on 25 February, 2022 - 20:23 )
Znanstvena Knjiga- Testo Scientifico - Scientific BookZnanstvena Knjiga- Testo Scientifico - Scientific Book
Scientific Pub 2019_Book_StemCellsAndAging.pdf
( 12 bytes, published on 25 February, 2022 - 20:23 )
Znanstvena publikacija - Pubblicazione - Scientific PublicationZnanstvena publikacija - Pubblicazione - Scientific Publication
Kodrič Scientific Pub Exp& Mol Medicine.pdf
( 3 bytes, published on 25 February, 2022 - 20:23 )

Objectives and Activities

MAIN OBJECTIVES OF THE PROJECT

The overall goal of ARTE was to encourage investments, entrepreneurial innovation, and competitiveness by improving cooperation between hospitals, Research Centers, Universities, SMEs, and Technology Parks in Regenerative Medicine. The focus is on new therapies for osteoarthritis and biomedical devices and services that make it possible to reduce costs. A public-private network has been created, which has favored the birth of an ecosystem connected to European initiatives and international investors.

POST-PROJECT IMPLEMENTATION RESULTS (25/02/2022)

Long-lasting effects produced by ARTE include the following:

• On 23/12/2022, AIFA - the Italian Medicines Agency approved the clinical trial proposal for knee osteoarthritis presented by the PP ASUFC, with the production of the drug using the VivaBioCell "GMP in a Box" NANT system.

• On 10/02/2022, VivaBioCell - together with the Slovenian Celica Biomed of Ljubljana, presented the approach to developing a cross-border Ecosystem for Advanced Therapies in the "Precision Medicine" workshop promoted at the Slovenian Pavilion of EXPO Dubai.

• On 23/02/2022, some companies of the cross-border ecosystem promoted a vital development project, called ARTE 3.0 on the Interreg Central Europe program, including Italy (Friuli-Venezia Giulia and Lombardy), Slovenia, Croatia, and Hungary.

Contacts

Tehnološki park Ljubljana d.o.o.

00386 (0) 16203406
Tehnološki park 19, 1000 Ljubljana, Slovenija
Rebeka Žerovnik

Ortopedska bolnišnica Valdoltra

00386 (0) 56696100
Jadranska cesta 31, 6280 Ankaran/Ancarano, Slovenija
Ingrid Milošev

Univerza v Ljubljani (Fakulteta za farmacijo)

00386 (0) 12418532
Kongresni trg 12, 1000 Ljubljana, Slovenija
Tilen Kranjc

VIVABIOCELL SPA

0039 0432545674
Via del Cotonificio 127, 33100 Udine, Italia
Antonio Sfiligoj

Azienda sanitaria universitaria Friuli Centrale

0039 04325543754278
Via Pozzuolo 330, 33100 Udine, Italia
Samantha Gomboso

Biovalley Investments S.p.A.

0039 0408992219
Via Flavia 23/1 34148 Trieste TS, Italia
Bravar Diego